Fate Therapeutics, Inc.2024财年实现净利润-1.86亿美元，同比减少15.53%

市场透视2025-03-10

3月10日，Fate Therapeutics, Inc.（FATE.US）公布财报，公告显示公司2024财年净利润为-1.86亿美元，同比减少15.53%；其中营业收入为13.63百万美元，同比减少78.55%，每股基本收益为-1.64美元。从资产负债表来看，Fate Therapeutics, Inc.（FATE.US）总负债1.22亿美元，其中短期债务7.42百万美元，资产负债比为3.62，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2518788289?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-10 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2518788289","market":"us","top_or_hot":-1,"title":"Fate Therapeutics, Inc.2024财年实现净利润-1.86亿美元，同比减少15.53%","media":"市场透视","content":"<div>\n<p>3月10日，Fate Therapeutics, Inc.（FATE.US）公布财报，公告显示公司2024财年净利润为-1.86亿美元，同比减少15.53%；其中营业收入为13.63百万美元，同比减少78.55%，每股基本收益为-1.64美元。从资产负债表来看，Fate Therapeutics, Inc.（FATE.US）总负债1.22亿美元，其中短期债务7.42百万美元，资产负债比为3.62，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000116abf1752b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fate Therapeutics, Inc.2024财年实现净利润-1.86亿美元，同比减少15.53%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFate Therapeutics, Inc.2024财年实现净利润-1.86亿美元，同比减少15.53%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-10 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000116abf1752b&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月10日，Fate Therapeutics, Inc.（FATE.US）公布财报，公告显示公司2024财年净利润为-1.86亿美元，同比减少15.53%；其中营业收入为13.63百万美元，同比减少78.55%，每股基本收益为-1.64美元。从资产负债表来看，Fate Therapeutics, Inc.（FATE.US）总负债1.22亿美元，其中短期债务7.42百万美元，资产负债比为3.62，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000116abf1752b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000116abf1752b&s=b","article_id":"2518788289","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000116abf1752b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2518788289","pubTimestamp":1741536051,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"3月10日，Fate Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.86亿美元，同比减少15.53%；其中营业收入为13.63百万美元，同比减少78.55%，每股基本收益为-1.64美元。机构评级：截至2025年3月10日，当前有11家机构对Fate Therapeutics, Inc.目标价做出预测，其中目标均价为6.64美元，其中最低目标价为3.00美元，最高目标价为12.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","FATE":"Fate Therapeutics Inc"},"translate_title":"Fate Therapeutics, Inc. achieved net profits of-$186 million in fiscal 2024, a year-on-year decrease of 15.53%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FATE":0.9,"LENZ":1},"content_text":"3月10日，Fate Therapeutics, Inc.（FATE.US）公布财报，公告显示公司2024财年净利润为-1.86亿美元，同比减少15.53%；其中营业收入为13.63百万美元，同比减少78.55%，每股基本收益为-1.64美元。从资产负债表来看，Fate Therapeutics, Inc.（FATE.US）总负债1.22亿美元，其中短期债务7.42百万美元，资产负债比为3.62，流动比率为0.08。机构评级：截至2025年3月10日，当前有11家机构对Fate Therapeutics, Inc.目标价做出预测，其中目标均价为6.64美元，其中最低目标价为3.00美元，最高目标价为12.00美元。公司简介：Fate Therapeutics Inc是一家总部位于美国的临床阶段生物制药公司。该公司致力于开发针对癌症和自身免疫性疾病的程序化细胞免疫疗法。该公司的细胞治疗产品线包括NK细胞和T细胞免疫肿瘤学项目，包括源自克隆主iPSC细胞系的现成工程候选产品，以及免疫调节项目，包括预防患者危及生命的并发症的候选产品。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518788289","isCrawlerRequest":true}